Document is current
Any future updates will be listed below
-
Authors
Cheng, Youshu
Dao, Cecilia
Zhou, Hang https://orcid.org/0000-0002-7694-6391
Li, Boyang
Kember, Rachel L. https://orcid.org/0000-0001-8820-2659
Toikumo, Sylvanus
Zhao, Hongyu https://orcid.org/0000-0003-1195-9607
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Justice, Amy C.
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (I01 BX004820)
U.S. Department of Veterans Affairs (I01 BX004820)
U.S. Department of Veterans Affairs (I01 BX004820)
U.S. Department of Veterans Affairs (I01 BX004820)
U.S. Department of Veterans Affairs (I01 BX004820)
U.S. Department of Veterans Affairs (I01 BX004820)
U.S. Department of Veterans Affairs (I01 BX004820)
U.S. Department of Veterans Affairs (I01 BX004820)
U.S. Department of Veterans Affairs (I01 BX004820)
U.S. Department of Veterans Affairs (I01 BX004820)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01 DA038632)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01 DA047063)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01 DA047820)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01 DA038632)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01 DA047063)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01 DA047820)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
- License Information
-
More Information
Article History
Received: 3 March 2023
Revised: 20 March 2023
Accepted: 22 March 2023
First Online: 5 May 2023
Competing interests
: HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka; and a holder of U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” issued 26 January 2021. The other authors have no competing interests to declare.
